课题基金 / 基金详情

Preparation of HLA-unrestricted anti-tumor cytotoxic T cells by gene transfer.

Preparation of HLA-unrestricted anti-tumor cytotoxic T cells by gene transfer.
通过基因转移制备 HLA 非限制性抗肿瘤细胞毒性 T 细胞。
批准号:
08670524
负责人:
HINODA Yuji
金额:
$1.22万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1996
资助国家:
日本
项目状态:
已结题
起止时间:
1996 至 1997

项目摘要

项目成果

HINODA Yuji的其他基金

相似基金

相关文献

中文摘要
翻译
本研究试图建立稳定的T细胞克隆,并将编码单链抗体和T细胞受体gannma链的cDNA融合基因转染T细胞。用RT-PCR方法从杂交瘤细胞总RNA中扩增出抗MUC 1粘蛋白单克隆抗体MUSE 11的重链和轻链cDNA,并将其连接起来作为单链抗体基因。将融合基因连接到逆转录病毒载体PG 1 EN中,瞬时转染包装细胞,获得病毒。然而,迄今为止已经获得了足以建立EB病毒转化的T细胞的稳定转染子的病毒滴度,现在正在评估病毒生产的各种条件。另一方面,我们最近利用含有融合蛋白基因的真核表达载体,通过常规的G418筛选获得了稳定的转染子。一些转染子克隆显示表达对MUC 1阳性培养的肿瘤细胞的结合活性。关于信号链抗体的表达水平、转染子与培养细胞结合的特异性等方面的详细研究正在进行中。还将检测T细胞受体γ链的信号转导和转染子的体内结合能力。
英文摘要
In this study, we attempted the establishment of the stable T cell clones transfected with a fusion gene consisting of cDNAs coding for single chain antibody and T cell receptor gannma chain. The VH and VL cDNAs of an anti-MUC1 mucin monoclonal antibody MUSE11 were amplified from total RNA extracted from hybridoma by RT-PCR method, then ligated them and used as the single chain antibody gene. The fusion gene was ligated into a retroviral vector PG1EN and transient transfection into packaging cells was performed to obtein viruses. However, the virus titer sufficient for establishing stable transfectans of EB virus-transformed T cells has thus far been obtained, being now evaluating various conditions of virus production. On the other hand, we have recently obtained thr stable transfectants using eukaryocytic expression vectoe haboring the fusin gene by conventional G418 selection. Some transfectant clones were shown to express the binding activity to MUC1-positive cultured tumor cells. Detailed studies on the expression level of signal chain antibody, the specificity of the binding of transfectants to cultured cells and so on are now under ongoing. Signal transduction of T cell receptor gamma chain and the binding ability of transfectants in vivo will be aiso examined.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
Noto H.et al.: "Cytotoxic T lymphocytes derived from bone marrow mononuclear cells recognize an underglycosylated form MUC1 mucin." Int.Immunol.9. 791-798 (1997)
Noto H.等人:“源自骨髓单核细胞的细胞毒性 T 淋巴细胞识别糖基化不足的形式 MUC1 粘蛋白。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Hinoda Y et al.: "Enhancement of reactivity of anti-MUC1 core protein antibody and killing activity of anti-MUC1 cytotoxic T cells by deglycosylation of target tissues or cells." J.Gastroenterol.33. 164-171 (1998)
Hinoda Y 等人:“通过靶组织或细胞的去糖基化增强抗 MUC1 核心蛋白抗体的反应性和抗 MUC1 细胞毒性 T 细胞的杀伤活性。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Noto H,et al.: "Cytotoxic T lymphocytes derived from bone marrow mononuclear cells recognize an underglycosylated form of MUC1 mucin." Int.Immunol.9. 791-798 (1997)
Noto H 等人:“源自骨髓单核细胞的细胞毒性 T 淋巴细胞识别糖基化不足形式的 MUC1 粘蛋白。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
日野田 裕治 他: "抗体分子工学と癌の遺伝子治療" 日臨免誌. 19. 453-459 (1996)
Yuji Hinoda 等:“抗体分子工程和癌症基因治疗”Nichinrin Menshi 19. 453-459 (1996)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Cell surface antigenic molecules as targets for immunotherapy
  • 批准号:
    17016049
  • 项目类别:
    Grant-in-Aid for Scientific Research on Priority Areas
  • 资助金额:
    $28.8万
  • 财政年份:
    2005
  • 负责人:
    HINODA Yuji
  • 依托单位:
Development of a new therapeutic modality with antisense suppression of MAdCAM-1 gene expression for inflammatory bowel diseases
  • 批准号:
    11670518
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.37万
  • 财政年份:
    1999
  • 负责人:
    HINODA Yuji
  • 依托单位:
海外基金